Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Josef Flammer

Showing results (11-20 of 152) with videos related to

Pageof 16
Sort By:
Journal of Clinical Medicine|September 28, 2021
Treatment of Glaucoma Patients with Flammer SyndromeKatarzyna Konieczka, Josef Flammer
Survey of Ophthalmology|December 6, 2007
What is the present pathogenetic concept of glaucomatous optic neuropathy?Josef Flammer, Maneli Mozaffarieh
Current Opinion in Ophthalmology|March 4, 2005
Blood flow in glaucomaMatthias C Grieshaber, Josef Flammer
The EPMA Journal|December 4, 2012
Predictive, preventive and personalised medicine for age-related macular degenerationPascal W Hasler, Josef Flammer
Survey of Ophthalmology|December 6, 2007
Does the blood-brain barrier play a role in Glaucoma?Matthias C Grieshaber, Josef Flammer
Survey of Ophthalmology|December 6, 2007
Fundamental sciences in glaucoma. IntroductionMatthias C Grieshaber, Josef Flammer
Progress in Retinal and Eye Research|September 8, 2009
Is the medication used to achieve the target intraocular pressure in glaucoma therapy of relevance?--an exemplary analysis on the basis of two beta-blockersMatthias C Grieshaber, Josef Flammer
Current Medical Research and Opinion|July 5, 2003
Experience with Cosopt, the fixed combination of timolol and dorzolamide, after switch from free combination of timolol and dorzolamide, in Swiss ophthalmologists' officesKonstantin Gugleta, Selim Orgül, Josef Flammer
Klinische Monatsblatter Fur Augenheilkunde|August 27, 2002
[Reproducibility of measurements with the retinal vessel analyzer under optimal conditions]Mona Pache, Edgar Nagel, Josef Flammer
The EPMA Journal|December 4, 2012
Predictive molecular profiling in blood of healthy vasospastic individuals: clue to targeted prevention as personalised medicine to effective costsKristina Yeghiazaryan, Josef Flammer, Olga Golubnitschaja
Pageof 16

Showing results (11-20 of 152) with videos related to

Sort By:
Pageof 16
Journal of Clinical Medicine|September 28, 2021
Treatment of Glaucoma Patients with Flammer SyndromeKatarzyna Konieczka, Josef Flammer
Survey of Ophthalmology|December 6, 2007
What is the present pathogenetic concept of glaucomatous optic neuropathy?Josef Flammer, Maneli Mozaffarieh
Current Opinion in Ophthalmology|March 4, 2005
Blood flow in glaucomaMatthias C Grieshaber, Josef Flammer
The EPMA Journal|December 4, 2012
Predictive, preventive and personalised medicine for age-related macular degenerationPascal W Hasler, Josef Flammer
Survey of Ophthalmology|December 6, 2007
Does the blood-brain barrier play a role in Glaucoma?Matthias C Grieshaber, Josef Flammer
Survey of Ophthalmology|December 6, 2007
Fundamental sciences in glaucoma. IntroductionMatthias C Grieshaber, Josef Flammer
Progress in Retinal and Eye Research|September 8, 2009
Is the medication used to achieve the target intraocular pressure in glaucoma therapy of relevance?--an exemplary analysis on the basis of two beta-blockersMatthias C Grieshaber, Josef Flammer
Current Medical Research and Opinion|July 5, 2003
Experience with Cosopt, the fixed combination of timolol and dorzolamide, after switch from free combination of timolol and dorzolamide, in Swiss ophthalmologists' officesKonstantin Gugleta, Selim Orgül, Josef Flammer
Klinische Monatsblatter Fur Augenheilkunde|August 27, 2002
[Reproducibility of measurements with the retinal vessel analyzer under optimal conditions]Mona Pache, Edgar Nagel, Josef Flammer
The EPMA Journal|December 4, 2012
Predictive molecular profiling in blood of healthy vasospastic individuals: clue to targeted prevention as personalised medicine to effective costsKristina Yeghiazaryan, Josef Flammer, Olga Golubnitschaja
Pageof 16